View More Recent Stories
-
Insulet Corporation (PODD) PT Raised to $330 at BTIG
-
Insulet (PODD) Tops Q1 EPS by 23c
-
William Blair Reiterates Outperform Rating on Insulet Corporation (PODD)
-
Canaccord Genuity Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD) Appoints Ashley McEvoy as President and CEO
-
Insulet's (PODD) RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
-
Insulet (PODD) Announces Pricing of Senior Notes Due 2033
-
Insulet (PODD) Announces Proposed $450M Financing Transactions
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
RBC Capital Starts Insulet Corporation (PODD) at Outperform
-
Insulet Corporation (PODD) PT Raised to $335 at Bernstein; 'Strong Q4, Great Setup for 2025'
-
Insulet Corporation (PODD) PT Raised to $293 at Stifel
-
Insulet Corporation (PODD) PT Raised to $324 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $310 at BTIG
-
Insulet (PODD) Tops Q4 EPS by 12c; offers outlook
-
Insulet (PODD) Launches Revolutionary Omnipod 5 in Five More Countries in Europe
-
Insulet Corporation (PODD) PT Raised to $324 at TD Cowen
-
Boston Scientific (BSX) PT Raised to $101 at BTIG
-
Insulet Corporation (PODD) PT Raised to $300 at BTIG
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Tandem Diabetes (TNDM) and Insulet (PODD) Volatility Attributed to Channel-Check Firm
-
Insulet (PODD) Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Insulet Corporation (PODD) PT Raised to $234 at Barclays
-
Insulet Corporation (PODD) PT Raised to $270 at BTIG
-
Insulet Corporation (PODD) PT Raised to $283 at Citi
-
Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
-
Bernstein SocGen Group Starts Insulet Corporation (PODD) at Outperform
-
Insulet Corporation (PODD) PT Raised to $269 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $285 at Piper Sandler
-
Buy this MedTech stock: Jefferies
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Piper Sandler Reiterates Overweight Rating on Insulet Corporation (PODD)
-
Oppenheimer Reiterates Outperform Rating on Insulet Corporation (PODD)
-
Jefferies Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD): Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
-
Selloff in MedTech stocks 'seems overdone': Citi
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Use the pullback to buy pullback in this MedTech stock: JPMorgan
-
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
-
Insulet (PODD) Misses Q2 EPS by 1c, provides guidance
-
Insulet (PODD) preliminary Q2 revenue of $488 million, estimate $460.4 million
-
MedTech stocks: Q2 earnings season preview
-
Insulet (PODD) Announces Omnipod 5 Launch in France and U.S. Innovation Updates
-
3 MedTech stocks to own - Citi

